Literature DB >> 2744907

Motor effects of locally administered pinaverium bromide in the sigmoid tract of patients with irritable bowel syndrome.

S Passaretti1, M Sorghi, E Colombo, G Mazzotti, A Tittobello, M Guslandi.   

Abstract

The effects of pinaverium bromide, a non-absorbable antispasmodic agent, administered locally, on sigmoid-rectal motility was investigated in 20 patients with irritable bowel syndrome. The influence of either pinaverium (10 subjects) or placebo (10 subjects) on a neostigmine-induced increase of sigmoid pressure was assessed and compared by means of computerized electromanometry. The drug was found to counteract significantly the motor effects of neostigmine, thus appearing to be an effective compound for the treatment of functional disorders of the colon.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744907

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

1.  Do calcium channel blockers and antimuscarinics protect against perforated colonic diverticular disease? A case control study.

Authors:  C R Morris; I M Harvey; W S L Stebbings; C T M Speakman; H J Kennedy; A R Hart
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier.

Authors:  A Rubinstein; R Radai; M Ezra; S Pathak; J S Rokem
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 3.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

Authors:  Lisa Ruepert; A Otto Quartero; Niek J de Wit; Geert J van der Heijden; Gregory Rubin; Jean Wm Muris
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

4.  Improvement of Quality of Nonanesthetic Colonoscopy by Preoperative Administration of Pinaverium Bromide.

Authors:  Xiao-Lin Wang; Jian-Ning Zhou; Li Ren; Xiao-Li Pan; Hong-Yu Ren; Jun Liu
Journal:  Chin Med J (Engl)       Date:  2017-03-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.